Andra AP fonden Decreases Stake in Humana Inc. (NYSE:HUM)

Andra AP fonden cut its stake in shares of Humana Inc. (NYSE:HUM) by 59.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,200 shares of the insurance provider’s stock after selling 22,100 shares during the quarter. Andra AP fonden’s holdings in Humana were worth $3,856,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HUM. FMR LLC increased its stake in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Humana by 55.6% in the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after buying an additional 214,535 shares in the last quarter. Retirement Systems of Alabama raised its stake in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares during the last quarter. Pzena Investment Management LLC boosted its position in shares of Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Humana in the 3rd quarter valued at about $50,102,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by insiders.

Humana Stock Down 2.2 %

Shares of HUM opened at $259.86 on Friday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company’s fifty day moving average is $271.80 and its two-hundred day moving average is $283.63. The firm has a market cap of $31.35 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays increased their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Truist Financial upped their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research note on Wednesday. Twenty equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.